Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease

This study is currently recruiting participants.
Verified May 2013 by Synageva BioPharma Corp.
Sponsor:
Information provided by (Responsible Party):
Synageva BioPharma Corp.
ClinicalTrials.gov Identifier:
NCT01371825
First received: June 9, 2011
Last updated: May 30, 2013
Last verified: May 2013
  Purpose

This is an open-label, repeat-dose, dose escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to LAL Deficiency. Eligible subjects will receive once-weekly doses of sebelipase alfa for up to three years.


Condition Intervention Phase
Lysosomal Acid Lipase Deficiency
Wolman Disease
Drug: Sebelipase alfa (SBC-102)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Resource links provided by NLM:


Further study details as provided by Synageva BioPharma Corp.:

Primary Outcome Measures:
  • Survival at 12 months of age [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Long-term safety of sebelipase alfa in children with growth failure due to LAL Deficiency [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
  • Survival beyond 12 months of age. [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: May 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Weekly IV infusions Dose A of sebelipase alfa
Drug: Sebelipase alfa (SBC-102)
Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with LAL Deficiency. Dosing will occur once weekly for up to three years.

Detailed Description:

Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by a marked decrease or almost complete absence of LAL, leading to the accumulation of lipids, predominately cholesteryl esters and triglycerides, in various tissues and cell types. In the liver, accumulation of lipids leads to hepatomegaly, liver dysfunction, and hepatic failure. Although a single disease, LAL Deficiency presents as a clinical continuum with two major phenotypes, Cholesteryl Ester Storage Disease (CESD) and Wolman Disease.

Early Onset LAL Deficiency (Wolman Disease) is extremely rare, with an estimated incidence of less than 2 lives per million. It is characterized by profound malabsorption, growth failure, and hepatic failure, and is usually fatal in the first year of life. There is currently no approved therapy for the treatment of LAL Deficiency.

  Eligibility

Ages Eligible for Study:   up to 24 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject's parent or legal guardian provides written informed consent/permission prior to any study procedures.
  • Male or female child with documented decreased LAL activity relative to the normal range of the lab performing the assay or documented result of molecular genetic testing (2 mutations) confirming a diagnosis.
  • Growth failure with onset before 6 months of age.

Exclusion Criteria:

  • Clinically important concurrent disease.
  • Has received an investigational product other than sebelipase alfa within 14 days prior to the first dose.
  • Subject is older than 24 months of age.
  • Myeloablative preparation, or other systemic pre-transplant conditioning, for hematopoietic stem cell or liver transplant.
  • Previous hematopoietic stem cell or liver transplant.
  • Known hypersensitivity to eggs.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01371825

Contacts
Contact: Amy Burke 781-357-9900 clinicaltrials@synageva.com

Locations
United States, California
University of California, Irvine Recruiting
Irvine, California, United States, 92697
Contact: Marie Wencel    949-824-0521    mwencel@uci.edu   
United States, New York
North Shore Hospital Long Island Jewish Health System Recruiting
Manhasset, New York, United States, 11030
Contact: Donna Bernstein, MS, CGC    516-365-3996 ext 2811    DBernst1@NSHS.edu   
Egypt
Not yet recruiting
Cairo, Egypt
France
Hopital Necker Enfants Malades Recruiting
Paris, France
Contact: Kim-Hanh Le Quan Sang    0144494375    kh.lequansang@nk.aphp.fr   
Germany
University of Mainz Not yet recruiting
Mainz, Germany
India
Not yet recruiting
Mumbai, India
Not yet recruiting
New Delhi, India
Italy
Azienda Ospedaliera Universita di Padova Recruiting
Padova, Italy
Contact: Andrea Bordugo       andrea.bordugo@sanita.padova.it   
Saudi Arabia
Not yet recruiting
Riyadh, Saudi Arabia
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Yin-Hsiu Chien, MD    886-2-23123456 ext 71937    chienyh@ntu.edu.tw   
Turkey
Recruiting
Ankara, Turkey
United Kingdom
St. Mary's Hospital, Central Manchester University Hospitals Recruiting
Manchester, United Kingdom
Contact: Kathryn McBride, RN    01619067500    kathryn.mcbride@wtcrf.nhs.uk   
Sponsors and Collaborators
Synageva BioPharma Corp.
  More Information

Publications:
Responsible Party: Synageva BioPharma Corp.
ClinicalTrials.gov Identifier: NCT01371825     History of Changes
Other Study ID Numbers: LAL-CL03
Study First Received: June 9, 2011
Last Updated: May 30, 2013
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
France: Agence nationale de sécurité du médicament
Germany: Bundesinstitut fur Arzneimittel und Medizinprodukte
Italy: Italian Medicines Agency (AIFA)
Taiwan: Department of Health

Keywords provided by Synageva BioPharma Corp.:
Wolman Disease
Acid Lipase Disease Deficiency, type 2
Cholesteryl Ester Storage Disease (CESD)
Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)
Wolman Disease (early onset LAL Deficiency)
Related Disorders:
Non-alcoholic Fatty Liver Disease (NAFLD)
Alcoholic Liver Disease
Niemann-Pick Disease (NPD) Type C
LIPA
Wolman Phenotype
Acid Lipase Deficiency
Acid Cholesteryl Hydrolase
Cholesteryl Ester Hydrolase Deficiency
LAL Deficiency
Late Onset Lysosomal Acid Lipase Deficiency (CESD)
Non-alcoholic Steatohepatitis (NASH)
Cryptogenic Cirrhosis
Chanarin Dorfman Syndrome

Additional relevant MeSH terms:
Wolman Disease
Cholesterol Ester Storage Disease
Growth Disorders
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Infant, Newborn, Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Failure to Thrive
Pathologic Processes
Lipidoses
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on April 16, 2014